Publications by authors named "Jozal Moore"

Claim this Profile
T
The impact of social determinants of health on outcomes of brexucabtagene autoleucel in adults with relapsed/refractory B-cell acute lymphoblastic leukemia.
Timothy E O'Connor, Chenyu Lin, Gregory W Roloff, Amy Zhang, Katharine Miller, Jozal Moore

Bone Marrow Transplant· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CAR HEMATOTOX independently predicts outcomes after CD19 CAR-T therapy for acute lymphoblastic leukemia.
Yannis K Valtis, Chenyu Lin, David Nemirovsky, Sean M Devlin, Kai Rejeski, Jozal Moore

Blood Adv· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Protocol of a decisional intervention for older adults with newly diagnosed acute myeloid leukemia and their caregivers: UR-GOAL 3.
Kah Poh Loh, Qiao Ming Rachel Ng, Supriya G Mohile, Sally Norton, Ronald M Epstein, Jozal Moore

J Geriatr Oncol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALL.
Gregory W Roloff, Ibrahim Aldoss, Noam E Kopmar, Chenyu Lin, Simone E Dekker, Jozal Moore

J Clin Oncol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of prior inotuzumab ozogamicin treatment on brexucabtagene autoleucel outcomes in adults with B-cell ALL.
Ibrahim Aldoss, Gregory W Roloff, Rawan Faramand, Noam E Kopmar, Chenyu Lin, Jozal Moore

Blood Adv· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
How Genetics Can Drive Initial Therapy Choices for Older Patients with Acute Myeloid Leukemia.
Jozal W Moore, Nancy Torres, Michael Superdock, Jason H Mendler, Kah Poh Loh

Curr Treat Options Oncol· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumor lysis syndrome risk in outpatient versus inpatient administration of venetoclax and hypomethlators for acute myeloid leukemia.
Ari Pelcovits, Jozal Moore, Brianna Bakow, Rabin Niroula, Pamela Egan

Support Care Cancer· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
False-positive heparin-PF4 latex immunoturbidimetric assay due to lupus anti-coagulant interference: a case report.
Hannah L McRae, Jozal W Moore, Jainulabdeen J Ifthikharuddin, Majed A Refaai

Br J Haematol· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Azacitidine and Venetoclax in AML.
Jozal W Moore, Aryeh Pelcovits, John L Reagan

N Engl J Med· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis